Rallybio (NASDAQ:RLYB) Major Shareholder Adar1 Capital Management, Llc Purchases 10,200 Shares of Stock

Rallybio Corporation (NASDAQ:RLYB) major shareholder Adar1 Capital Management, Llc acquired 10,200 shares of the business’s stock in a transaction on Tuesday, May 19th. The stock was acquired at an average price of $13.98 per share, for a total transaction of $142,596.00. Following the acquisition, the insider owned 926,352 shares of the company’s stock, valued at approximately $12,950,400.96. This trade represents a 1.11% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Large shareholders that own 10% or more of a company’s stock are required to disclose their sales and purchases with the SEC.

Adar1 Capital Management, Llc also recently made the following trade(s):

• On Monday, May 18th, Adar1 Capital Management, Llc bought 6,009 shares of Rallybio stock. The shares were acquired at an average cost of $13.98 per share, with a total value of $84,005.82.
• On Friday, May 15th, Adar1 Capital Management, Llc bought 300 shares of Rallybio stock. The shares were acquired at an average cost of $13.90 per share, with a total value of $4,170.00.
• On Wednesday, May 13th, Adar1 Capital Management, Llc bought 79,259 shares of Rallybio stock. The shares were acquired at an average cost of $13.99 per share, with a total value of $1,108,833.41.
• On Tuesday, May 12th, Adar1 Capital Management, Llc bought 800 shares of Rallybio stock. The shares were acquired at an average cost of $13.83 per share, with a total value of $11,064.00.
• On Monday, May 11th, Adar1 Capital Management, Llc acquired 50,000 shares of Rallybio stock. The shares were bought at an average cost of $14.00 per share, with a total value of $700,000.00.
• On Tuesday, May 5th, Adar1 Capital Management, Llc acquired 35,101 shares of Rallybio stock. The shares were bought at an average cost of $14.00 per share, with a total value of $491,414.00.
• On Monday, May 4th, Adar1 Capital Management, Llc acquired 120,804 shares of Rallybio stock. The shares were bought at an average cost of $13.97 per share, with a total value of $1,687,631.88.

Rallybio Stock Up 2.7%

RLYB stock opened at $14.58 on Thursday. Rallybio Corporation has a twelve month low of $2.16 and a twelve month high of $15.31. The firm has a market cap of $77.27 million, a PE ratio of -3.20 and a beta of -1.10. The business has a 50 day moving average of $10.05 and a 200 day moving average of $7.25.

Rallybio (NASDAQ:RLYB) last posted its quarterly earnings data on Wednesday, May 13th. The company reported ($1.46) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.20) by ($0.26). Rallybio had a negative net margin of 911.07% and a negative return on equity of 55.79%. The company had revenue of $0.21 million for the quarter, compared to the consensus estimate of $0.21 million.

Institutional Trading of Rallybio

Several institutional investors have recently added to or reduced their stakes in RLYB. Citadel Advisors LLC boosted its stake in Rallybio by 576.1% during the 3rd quarter. Citadel Advisors LLC now owns 438,705 shares of the company’s stock valued at $219,000 after purchasing an additional 373,821 shares during the last quarter. Susquehanna International Group LLP grew its holdings in shares of Rallybio by 485.9% in the third quarter. Susquehanna International Group LLP now owns 136,294 shares of the company’s stock worth $68,000 after acquiring an additional 113,031 shares during the period. Geode Capital Management LLC increased its position in Rallybio by 1.2% during the fourth quarter. Geode Capital Management LLC now owns 248,005 shares of the company’s stock valued at $170,000 after acquiring an additional 2,996 shares during the last quarter. Renaissance Technologies LLC increased its position in Rallybio by 16.9% during the fourth quarter. Renaissance Technologies LLC now owns 835,692 shares of the company’s stock valued at $573,000 after acquiring an additional 120,892 shares during the last quarter. Finally, XTX Topco Ltd increased its position in Rallybio by 64.6% during the fourth quarter. XTX Topco Ltd now owns 97,313 shares of the company’s stock valued at $67,000 after acquiring an additional 38,205 shares during the last quarter. 90.34% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of research analysts recently weighed in on the company. Wall Street Zen raised Rallybio to a “hold” rating in a research report on Saturday, March 28th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Rallybio in a research report on Friday, May 8th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the company currently has an average rating of “Sell”.

About Rallybio

Rallybio Therapeutics, Inc (NASDAQ: RLYB) is a clinical‐stage biotechnology company focused on developing and commercializing therapies for people living with rare genetic diseases. The company’s scientific approach leverages diverse modalities—including monoclonal antibodies, small molecules and enzyme replacement—to address high‐unmet‐need conditions in areas such as immunodeficiency, metabolic disorders and dermatologic diseases. Rallybio’s pipeline is designed to advance through registrational clinical trials with the goal of delivering first‐in‐class or best‐in‐class therapies to patients who currently have limited or no approved treatment options.

Among Rallybio’s lead programs is RBX‐100, an investigational therapy for congenital athymia, a rare pediatric immunodeficiency.